The results demonstrated promising the anti-tumor activity and safety of pembrolizumab for PD-L1-positive GC/GEJC patients (TPS high) and highlighted the significance of measuring PD-L1 expression in mononuclear inflammatory cells [14]. This evidence concerns the gene CD274 and neoplasm.